title: Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.
abstract: BACKGROUND
  The pathology causing progressive aphasia is typically a variant of frontotemporal lobar degeneration, especially with ubiquitin-positive inclusions (FTLD-U). Less commonly the underlying pathology is Alzheimer disease (AD).
  
  
  OBJECTIVE
  To compare clinicopathologic and MRI features of subjects with progressive aphasia and AD pathology to subjects with aphasia and FTLD-U pathology and subjects with typical AD.
  
  
  METHODS
  We identified 5 subjects with aphasia and AD pathology and 5 with aphasia and FTLD-U pathology with an MRI from a total of 216 aphasia subjects. Ten subjects with typical AD clinical features and AD pathology were also identified. All subjects with AD pathology underwent pathologic reanalysis with TDP-43 immunohistochemistry. Voxel-based morphometry (VBM) was used to assess patterns of gray matter atrophy in the aphasia cases with AD pathology, aphasia cases with FTLD-U, and typical AD cases with AD pathology, compared with a normal control group.
  
  
  RESULTS
  All aphasic subjects had fluent speech output. However, those with AD pathology had better processing speed than those with FTLD-U pathology. Immunohistochemistry with TDP-43 antibodies was negative. VBM revealed gray matter atrophy predominantly in the temporoparietal cortices, with notable sparing of the hippocampus in the aphasia with AD subjects. In comparison, the aphasic subjects with FTLD-U showed sparing of the parietal lobe. Typical AD subjects showed temporoparietal and hippocampal atrophy.
  
  
  CONCLUSIONS
  A temporoparietal pattern of atrophy on MRI in patients with progressive fluent aphasia and relatively preserved processing speed is suggestive of underlying Alzheimer disease pathology rather than frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. josephs.keith@mayo.edu
authors.forename: K A
authors.initials: KA
authors.lastname: Josephs
authors.forename: J L
authors.initials: JL
authors.lastname: Whitwell
authors.forename: J R
authors.initials: JR
authors.lastname: Duffy
authors.forename: W A
authors.initials: WA
authors.lastname: Vanvoorst
authors.forename: E A
authors.initials: EA
authors.lastname: Strand
authors.forename: W T
authors.initials: WT
authors.lastname: Hu
authors.forename: B F
authors.initials: BF
authors.lastname: Boeve
authors.forename: N R
authors.initials: NR
authors.lastname: Graff-Radford
authors.forename: J E
authors.initials: JE
authors.lastname: Parisi
authors.forename: D S
authors.initials: DS
authors.lastname: Knopman
authors.forename: D W
authors.initials: DW
authors.lastname: Dickson
authors.forename: C R
authors.initials: CR
authors.lastname: Jack
authors.forename: R C
authors.initials: RC
authors.lastname: Petersen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology*; D001037:Aphasia / Q000378:metabolism / Q000473:pathology*; D001931:Brain Mapping; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D002479:Inclusion Bodies / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D009483:Neuropsychological Tests; D012189:Retrospective Studies; D025801:Ubiquitin / Q000378:metabolism*
chemical_list: D025801:Ubiquitin